Showing results (261-270 of 509) with videos related to
Sort By:
Pageof 51
Environmental Pollution (Barking, Essex : 1987)|December 12, 2022
Association of single and joint metals with albuminuria and estimated glomerular filtration longitudinal change in middle-aged adults from Spain: The Aragon workers health studyMaria Grau-Perez, Arce Domingo-Relloso, Tamara Garcia-Barrera, et al.Journal of Hypertension|April 15, 2016
Impact of hypertension on mortality and cardiovascular disease burden in patients with cardiovascular risk factors from a general practice setting: the ESCARVAL-risk studyJosep Redon, Maria Tellez-Plaza, Domingo Orozco-Beltran, et al.Hypertension (Dallas, Tex. : 1979)|January 28, 2009
Prevalence and factors associated with circadian blood pressure patterns in hypertensive patientsAlejandro de la Sierra, Josep Redon, José R Banegas, et al.American Journal of Nephrology|September 4, 2018
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER StudyRajiv Agarwal, Patrick Rossignol, Dahlia Garza, et al.European Heart Journal|March 26, 2019
Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY RegistryFelix Mahfoud, Michael Böhm, Roland Schmieder, et al.Diabetes, Obesity & Metabolism|September 6, 2019
Intensive glucose-lowering and the risk of vascular events and premature death in patients with decreased kidney function: The ADVANCE trialToshiaki Ohkuma, Sophia Zoungas, Min Jun, et al.Journal of Occupational and Environmental Medicine|October 30, 2013
Pesticide risk perception and biomarkers of exposure in Florida female farmworkersJennifer D Runkle, J Antonio Tovar-Aguilar, Eugenia Economos, et al.Hypertension (Dallas, Tex. : 1979)|December 11, 2013
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trialJohn Chalmers, Hisatomi Arima, Mark Woodward, et al.Lancet (London, England)|September 20, 2019
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialRajiv Agarwal, Patrick Rossignol, Alain Romero, et al.Journal of Hypertension|June 29, 2017
Expertise: no longer a sine qua non for guideline authors?Franz H Messerli, Louis Hofstetter, Enrico Agabiti-Rosei, et al.Pageof 51